FM
TYRA icon

Frazier Management’s Tyra Biosciences TYRA Stock Holding History

Frazier Management’s Portfolio TYRA Stock Details TYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,250,000
Closed -$17.6M – 29
2021
Q4 		$17.6M Hold
1,250,000
– – 1.35% 26
2021
Q3 		$22M Buy
+1,250,000
New +$23.9M 1.76% 18

Other funds holding TYRA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CPX
Canaan Partners XI Menlo Park, California $127M AUM 217.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Frazier Management's TYRA Position: Q1 2022 in Review

Frazier Management sold out of Tyra Biosciences (TYRA) in Q1 2022, closing a stake of 1,250,000 shares — an estimated $17.6M sold.

Frazier Management first reported a position in TYRA in Q3 2021 and held it in 2 quarters. The position peaked at $22M in Q3 2021. 46 funds tracked by Wall St. Rank hold TYRA as of Q1 2022.

  • Frazier Management reported no remaining Tyra Biosciences position as of Q1 2022 after selling out during the quarter.
  • Frazier Management sold 1,250,000 Tyra Biosciences shares in Q1 2022, an estimated $17.6M.
  • Frazier Management first reported a position in Tyra Biosciences in Q3 2021 and held it in 2 quarters.
  • Frazier Management's Tyra Biosciences position peaked at $22M in Q3 2021.
  • 46 funds tracked by Wall St. Rank held Tyra Biosciences as of Q1 2022.

Based on Frazier Management's 13F filing for Q1 2022, filed 13 May 2022.